HC Wainwright Begins Coverage on Coherus Oncology (NASDAQ:CHRS)

Investment analysts at HC Wainwright started coverage on shares of Coherus Oncology (NASDAQ:CHRS) in a report issued on Thursday, Marketbeat Ratings reports. The firm set a “buy” rating on the biotechnology company’s stock.

Separately, Weiss Ratings raised shares of Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Coherus Oncology Trading Down 0.0%

Shares of NASDAQ CHRS traded down $0.00 during midday trading on Thursday, reaching $0.90. 949,886 shares of the stock were exchanged, compared to its average volume of 1,496,376. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.77 and a quick ratio of 1.70. The company has a market capitalization of $138.74 million, a price-to-earnings ratio of -0.87 and a beta of 0.98. The business has a 50-day simple moving average of $1.21 and a two-hundred day simple moving average of $1.53. Coherus Oncology has a 12 month low of $0.81 and a 12 month high of $2.62.

Coherus Oncology (NASDAQ:CHRS) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.06. The firm had revenue of $14.31 million for the quarter, compared to analyst estimates of $14.41 million. Coherus Oncology had a negative net margin of 259.41% and a negative return on equity of 222.75%. As a group, equities research analysts expect that Coherus Oncology will post -0.88 EPS for the current year.

Institutional Trading of Coherus Oncology

Several institutional investors have recently modified their holdings of CHRS. BlackRock Inc. acquired a new position in shares of Coherus Oncology during the second quarter valued at about $16,805,000. GSA Capital Partners LLP acquired a new position in Coherus Oncology during the 2nd quarter worth approximately $531,000. Deutsche Bank AG bought a new position in Coherus Oncology in the second quarter worth approximately $179,000. Bank of America Corp DE grew its position in Coherus Oncology by 190.2% in the 1st quarter. Bank of America Corp DE now owns 324,133 shares of the biotechnology company’s stock valued at $548,000 after purchasing an additional 212,430 shares during the period. Finally, Jefferies Financial Group Inc. acquired a new position in Coherus Oncology during the second quarter worth $353,000. Institutional investors own 72.82% of the company’s stock.

Coherus Oncology Company Profile

Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.